Advaxis Inc. (NASDAQ:ADXS)’s share price dropped 2.3% during trading on Thursday . The stock traded as low as $8.44 and last traded at $8.48, with a volume of 325,778 shares changing hands. The stock had previously closed at $8.68.

ADXS has been the topic of several recent research reports. FBR & Co reaffirmed a “positive” rating and set a $34.00 target price on shares of Advaxis in a report on Tuesday, March 29th. Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a report on Friday, June 10th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Advaxis in a report on Thursday, April 21st. Six equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $24.80.

The company has a 50 day moving average of $8.48 and a 200-day moving average of $8.19. The company’s market capitalization is $294.35 million.

In other news, Director Thomas J. Mckearn sold 4,100 shares of the business’s stock in a transaction on Friday, May 13th. The shares were sold at an average price of $7.45, for a total value of $30,545.00. Following the transaction, the director now owns 82,120 shares of the company’s stock, valued at $611,794. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel O’connor sold 8,237 shares of the business’s stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $7.51, for a total transaction of $61,859.87. Following the completion of the transaction, the chief executive officer now directly owns 316,661 shares in the company, valued at approximately $2,378,124.11. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Advaxis stock. Oxford Asset Management bought a new stake in Advaxis Inc. (NASDAQ:ADXS) during the fourth quarter, Holdings Channel reports. The institutional investor bought 146,282 shares of the biotechnology company’s stock, valued at approximately $1,502,000. Oxford Asset Management owned 0.43% of Advaxis at the end of the most recent quarter.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.